Acasti Pharma Inc. (ACST)
NASDAQ: ACST
· Real-Time Price · USD
3.37
0.13 (4.01%)
At close: Oct 25, 2024, 10:00 PM
Acasti Pharma Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | 4.83M | n/a | n/a | n/a | n/a | -32K | -32K | -32K | -32K | n/a | n/a | n/a | n/a | 115K | 196K | 196K |
Cost of Revenue | 9.66M | 4.83M | 7.88M | 5.14M | 9.59M | 23.67M | 24.87M | 27.89M | 28.17M | 26.11M | 26.33M | 24.79M | 20.06M | 8.08M | 3.64M | 9.69M |
Gross Profit | -4.83M | -4.83M | -7.88M | -5.14M | -9.59M | -23.7M | -24.91M | -27.92M | -28.2M | -26.11M | -21.86M | -20.32M | -15.59M | -3.49M | -3.45M | -9.5M |
Operating Income | n/a | -14.13M | -18.17M | -16.18M | -15.67M | -16.95M | -18.66M | -20.93M | -22.56M | -18.45M | -17.18M | -15.63M | -12.69M | -13.56M | -11.05M | -15.52M |
Interest Income | n/a | 656K | 1.07M | 1.19M | 1.13M | 1.07M | 719.46K | 481.23K | 335.72K | 214.72K | 187.72K | 152K | 259K | 223K | 221K | 222K |
Pretax Income | -12.77M | -16.44M | -14.28M | -13.71M | -14.69M | -61.93M | -63.49M | -64.86M | -65.31M | -18.57M | -18.18M | -12.12M | -10.47M | -11.56M | -11M | -18.13M |
Net Income | -12.77M | -13.97M | -11.61M | -11.45M | -12.85M | -38.77M | -40.27M | -41.93M | -42.43M | -17.25M | -17.14M | -11.22M | -9.82M | -11.56M | -11M | -18.13M |
Selling & General & Admin | 7.17M | 7.16M | 7.25M | 7.61M | 7.01M | 7.98M | 8.16M | 7.77M | 8.21M | 7.77M | 8.04M | 9.15M | 9.73M | 9.16M | 8.45M | 6.97M |
Research & Development | 9.51M | 9.56M | 8.81M | 6.3M | 4.68M | 4.64M | 5.64M | 8.48M | 9.97M | 10.66M | 10.39M | 7.68M | 5.56M | 3.85M | 2.35M | 2.68M |
Other Expenses | n/a | 38K | 38K | 37K | 1.52M | 1.31M | 1.33M | 1.32M | -121K | 54K | 283K | 295K | 249K | -254K | -503K | -498K |
Operating Expenses | 16.68M | 16.76M | 16.1M | 13.27M | 12.77M | 13.67M | 14.87M | 17.97M | 18.25M | 18.49M | 18.47M | 14.58M | 13M | 10.97M | 8.75M | 10.27M |
Interest Expense | n/a | 235K | 551K | 763K | 662K | 681K | 365K | 189K | 55K | 69K | 69K | 33K | 172K | 182K | 182K | 182K |
Selling & Marketing Expenses | n/a | 61K | 91K | 149.4K | 209.4K | 199.4K | 241.4K | 186K | 136K | 340K | 30K | 2K | -8K | -197K | 267K | 426K |
Cost & Expenses | 17.81M | 13.06M | 16.92M | 16.19M | 17.11M | 18.02M | 19.88M | 20.89M | 21.18M | 22.56M | 21.66M | 20.12M | 17.09M | 13.96M | 11.17M | 15.62M |
Income Tax Expense | n/a | -2.46M | -2.67M | -2.27M | -1.83M | -9.81M | -9.88M | -9.59M | -9.54M | -1.2M | -929K | -774K | -532K | 3.76M | 3.76M | 3.76M |
Shares Outstanding (Basic) | 12.09M | 11.51M | 11.51M | 10.93M | 9.4M | 7.44M | 7.55M | 7.44M | 7.43M | 7.43M | 7.42M | 7.39M | 7.38M | 7.38M | 5.46M | 4.34M |
Shares Outstanding (Diluted) | 12.09M | 11.51M | 11.51M | 10.93M | 9.4M | 7.44M | 7.55M | 7.44M | 7.43M | 7.43M | 7.42M | 7.39M | 7.38M | 7.38M | 5.46M | 4.34M |
EPS (Basic) | -0.79 | -1.24 | -1.2 | -1.33 | -1.63 | -5.2 | -5.4 | -5.63 | -5.7 | -2.33 | -2.32 | -1.48 | -1.59 | -2.35 | -2.89 | -5.07 |
EPS (Diluted) | -0.79 | -1.24 | -1.2 | -1.33 | -1.63 | -5.2 | -5.4 | -5.63 | -5.7 | -2.33 | -2.32 | -1.48 | -1.59 | -2.35 | -3.38 | -5.58 |
EBITDA | -10.41M | -13.02M | -16.06M | -13.32M | -12.27M | -13.2M | -14.38M | -17.41M | -18.06M | -18.31M | -18.31M | -16.76M | -15.34M | -16.58M | -14.32M | -13.12M |
EBIT | n/a | -13.06M | -16.1M | -13.36M | -11.37M | -12.27M | -13.47M | -16.49M | -18.25M | -18.49M | -18.47M | -16.93M | -15.34M | -16.58M | -14.32M | -13.5M |
Depreciation & Amortization | n/a | 4K | 5K | 5K | 11K | 18K | 27K | -36K | 124K | 298K | 130K | 483.63K | 428.63K | 247.63K | 443.63K | 526K |